A187660 Stock Overview
A contract research organization, provides clinical services in Asia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Hyundai ADM Bio Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,165.00 |
| 52 Week High | ₩3,970.00 |
| 52 Week Low | ₩1,876.00 |
| Beta | 0.96 |
| 11 Month Change | -16.71% |
| 3 Month Change | 9.52% |
| 1 Year Change | 40.04% |
| 33 Year Change | -25.79% |
| 5 Year Change | n/a |
| Change since IPO | -67.97% |
Recent News & Updates
Is ADM Korea (KOSDAQ:187660) Using Debt Sensibly?
Sep 02
Optimistic Investors Push ADM Korea Inc. (KOSDAQ:187660) Shares Up 36% But Growth Is Lacking
Mar 21Revenues Not Telling The Story For ADM Korea Inc. (KOSDAQ:187660) After Shares Rise 36%
Mar 21Shareholder Returns
| A187660 | KR Life Sciences | KR Market | |
|---|---|---|---|
| 7D | -5.8% | -7.6% | -0.7% |
| 1Y | 40.0% | 32.0% | -4.1% |
Return vs Industry: A187660 exceeded the KR Life Sciences industry which returned 32% over the past year.
Return vs Market: A187660 exceeded the KR Market which returned -4.1% over the past year.
Price Volatility
| A187660 volatility | |
|---|---|
| A187660 Average Weekly Movement | 7.8% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in KR Market | 11.5% |
| 10% least volatile stocks in KR Market | 2.7% |
Stable Share Price: A187660 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A187660's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 170 | Hyun-woo Kim | hdadmbio.com |
Hyundai ADM Bio Inc., a contract research organization, provides clinical services in Asia. It offers clinical development services, such as medical writing, clinical operation, late phase study, data management, biostatistics, and regulatory affairs. The company also provides pharmacovigilance services, which include case processing and safety reporting, safety and risk management plans, aggregate reporting, literature screening, and medical device vigilance; and quality assurance services.
Hyundai ADM Bio Inc. Fundamentals Summary
| A187660 fundamental statistics | |
|---|---|
| Market cap | ₩67.69b |
| Earnings (TTM) | -₩15.87b |
| Revenue (TTM) | ₩11.56b |
5.8x
P/S Ratio-4.2x
P/E RatioIs A187660 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A187660 income statement (TTM) | |
|---|---|
| Revenue | ₩11.56b |
| Cost of Revenue | ₩10.46b |
| Gross Profit | ₩1.10b |
| Other Expenses | ₩16.97b |
| Earnings | -₩15.87b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -750.34 |
| Gross Margin | 9.51% |
| Net Profit Margin | -137.29% |
| Debt/Equity Ratio | 58.2% |
How did A187660 perform over the long term?
See historical performance and comparison